Head to Head Comparison: Delcath Systems (DCTH) and Its Peers

Delcath Systems (NASDAQ:DCTH – Get Free Report) is one of 510 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its rivals? We will compare Delcath Systems to similar companies based on the strength of its risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.

Risk & Volatility

Delcath Systems has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Delcath Systems’ rivals have a beta of 2.63, indicating that their average share price is 163% more volatile than the S&P 500.

Valuation & Earnings

This table compares Delcath Systems and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Delcath Systems $85.23 million $2.70 million 118.01
Delcath Systems Competitors $1.90 billion $138.28 million 5.93

Delcath Systems’ rivals have higher revenue and earnings than Delcath Systems. Delcath Systems is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings for Delcath Systems and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Delcath Systems 0 1 2 1 3.00
Delcath Systems Competitors 4323 10552 18356 839 2.46

Delcath Systems presently has a consensus price target of $29.33, indicating a potential upside of 55.36%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 28.20%. Given Delcath Systems’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Delcath Systems is more favorable than its rivals.

Profitability

This table compares Delcath Systems and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Delcath Systems 6.05% 5.56% 4.98%
Delcath Systems Competitors -191.42% -197.84% -21.82%

Institutional & Insider Ownership

61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 19.4% of Delcath Systems shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Delcath Systems beats its rivals on 9 of the 13 factors compared.

About Delcath Systems

(Get Free Report)

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.